ストックスクリーナーアプリを入手
1.35
2.27%
0.03
アフターアワーズ：
1.38
0.03
+2.22%
前日終値:
$1.32
開ける：
$1.33
24時間の取引高:
3.73M
Relative Volume:
0.62
時価総額：
$419.31M
収益：
$160.03M
当期純損益:
$-128.58M
株価収益率:
-3.1631
EPS:
-0.4268
ネットキャッシュフロー:
$-121.21M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
+20.54%
6か月 パフォーマンス:
-33.17%
1年 パフォーマンス:
-2.17%
1日の値動き範囲:
$1.3209
$1.3962
1週間の範囲:
$1.30
$1.4399
52週間の値動き範囲:
$1.09
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.35 | 409.99M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
90.62 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
310.58 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.32 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.92 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.58 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-11-11 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-14 | 開始されました | Stephens | Overweight |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-17 | アップグレード | UBS | Neutral → Buy |
| 2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-06-30 | 開始されました | Goldman | Buy |
| 2023-05-10 | 開始されました | Barclays | Equal Weight |
| 2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 開始されました | UBS | Neutral |
| 2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Neutral |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-09-27 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 開始されました | Cowen | Outperform |
| 2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | ダウングレード | CL King | Buy → Neutral |
| 2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2016-06-27 | 開始されました | CL King | Buy |
| 2016-04-15 | 開始されました | First Analysis Sec | Overweight |
| 2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-02-04 | 繰り返されました | Maxim Group | Buy |
| 2013-09-26 | 繰り返されました | Maxim Group | Buy |
| 2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California Company Profile & Introduction - Moomoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026) – Minichart - Minichart
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike - Stock Titan
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant - Stock Titan
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58 - Stock Titan
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant - Stock Titan
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price - Stock Titan
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan - TradingView
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price - Stock Titan
Director John Milligan receives 223,492 options at PacBio (PACB) - Stock Titan
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58 - Stock Titan
Pacific Biosciences (PACB) shareholders approve 16M-share equity plan increase and 2026 auditor - Stock Titan
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Zacks Investment Research
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Q1 Earnings Highs And Lows: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks - The Globe and Mail
Insiders At Pacific Biosciences of California Sold US$1.3m In Stock, Alluding To Potential Weakness - Moomoo
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology - TradingView
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PACB Q1 2026 Earnings: EPS Beats Estimates, Stock Surges 14%Fiscal Year Earnings - newsline.com
PacBio (PACB) Launches New Sequencing Technology for Global Dist - GuruFocus
Pacbio Ships Sprq-Nx Chemistry and Multi-Use Smrt Cells for Revio Hifi Sequencing Platform Worldwide - marketscreener.com
PacBio ships new sequencing chemistry, cuts genome cost By Investing.com - Investing.com Canada
PacBio ships new sequencing chemistry, cuts genome cost - Investing.com
AI-tuned PacBio upgrade brings sub-$300 human genomes at scale - Stock Titan
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing - Yahoo Finance
Pacific Biosciences: Pressure Is Rising (NASDAQ:PACB) - Seeking Alpha
PACB (Pacific Biosciences of California) ROC % : -47.66% (As of Mar. 2026) - GuruFocus
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
PacBio to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
Pacific Biosciences of California sets $300 price point for 20x human genome sequencing on Revio - Traders Union
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology - TradingView
PACB Secures $7.2M in Seed Funding and Partners with Blank Bio - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology - BioSpace
AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA - Stock Titan
PacBio tumbles after narrowing full-year revenue guidance - MSN
Sequencing constraints lifted as Pacific Biosciences of California enables combined genetic and methylation detection - Traders Union
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month - MSN
Pacific Biosciences of California introduces HiFi Starter Kit to expand long-read sequencing access - Traders Union
Pacific Biosciences stock (US6932471010): Latest developments and market position - AD HOC NEWS
PACB SEC FilingsPacific Biosc 10-K, 10-Q, 8-K Forms - Stock Titan
PACB Technical Analysis | Trend, Signals & Chart Patterns | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PacBio (PACB) Q1 earnings report preview: What to look for - MSN
Pacific Biosciences (PACB) Reports Q1 EPS - Yahoo Finance
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.43%
大文字化:
|
ボリューム (24 時間):